Hallal Ferreira Raro O, Nordmann P, Dominguez Pino M, Findlay J, Poirel L. Emergence of carbapenemase-producing Hypervirulent Klebsiella pneumoniae in Switzerland. Antimicrob Agents Chemother. 2023;67:e0142422. https://doi.org/10.1128/aac.01424-22.

Article  CAS  PubMed  Google Scholar 

Titov I, Wunderink RG, Roquilly A, Rodriguez Gonzalez D, David-Wang A, Boucher HW, et al. A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem/cilastatin/relebactam versus piperacillin/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 Study). Clin Infect Dis. 2021;73:e4539–48. https://doi.org/10.1093/cid/ciaa803.

Article  PubMed  Google Scholar 

Castanheira M, Deshpande LM, Mendes RE, Doyle TB, Sader HS. Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents. JAC Antimicrob Resist. 2022;4:dlac098. https://doi.org/10.1093/jacamr/dlac098.

Article  PubMed  PubMed Central  Google Scholar 

Papadimitriou-Olivgeris M, Bartzavali C, Karachalias E, Spiliopoulou A, Tsiata E, Siakallis G, et al. A seven-year microbiological and molecular study of bacteremias due to carbapenemase-producing Klebsiella pneumoniae: an interrupted time-series analysis of changes in the carbapenemase gene’s distribution after introduction of ceftazidime/avibactam. Antibiotics. 2022;11. https://doi.org/10.3390/antibiotics11101414.

Bonnin RA, Bernabeu S, Emeraud C, Naas T, Girlich D, Jousset AB, et al. In vitro activity of imipenem-relebactam, meropenem-vaborbactam, ceftazidime–avibactam and comparators on carbapenem-resistant non-carbapenemase-producing enterobacterales. Antibiotics. 2023;12. https://doi.org/10.3390/antibiotics12010102.

Bhatnagar A, Boyd S, Sabour S, Bodnar J, Nazarian E, Peinovich N, et al. Aztreonam–avibactam susceptibility testing program for metallo-beta-lactamase-producing enterobacterales in the antibiotic resistance laboratory network, March 2019 to December 2020. Antimicrob Agents Chemother. 2021;65:e0048621. https://doi.org/10.1128/aac.00486-21.

Article  CAS  PubMed  Google Scholar 

Esposito S, Stone GG, Papaparaskevas J. In vitro activity of aztreonam/avibactam against a global collection of Klebsiella pneumoniae collected from defined culture sources in 2016 and 2017. J Glob Antimicrob Resist. 2021;24:14–22. https://doi.org/10.1016/j.jgar.2020.08.004.

Article  CAS  PubMed  Google Scholar 

Lee TD, Adie K, McNabb A, Purych D, Mannan K, Azana R, et al. Rapid detection of KPC, NDM, and OXA-48-like carbapenemases by real-time PCR from rectal swab surveillance samples. J Clin Microbiol. 2015;53:2731–3. https://doi.org/10.1128/jcm.01237-15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mauri C, Maraolo AE, Di Bella S, Luzzaro F, Principe L. The revival of aztreonam in combination with avibactam against metallo-beta-lactamase-producing gram-negatives: a systematic review of in vitro studies and clinical cases. Antibiotics. 2021;10. https://doi.org/10.3390/antibiotics10081012.

Lee CR, Lee JH, Park KS, Kim YB, Jeong BC, Lee SH. Global dissemination of carbapenemase-producing Klebsiella pneumoniae: epidemiology, genetic context, treatment options, and detection methods. Front Microbiol. 2016;7:895. https://doi.org/10.3389/fmicb.2016.00895.

Article  PubMed  PubMed Central  Google Scholar 

Livermore DM, Andrews JM, Hawkey PM, Ho PL, Keness Y, Doi Y, et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother. 2012;67:1569–77.

Article  CAS  PubMed  Google Scholar 

Livermore DM, Mushtaq S, Vickers A, Woodford N. Activity of aztreonam/avibactam against metallo-beta-lactamase-producing enterobacterales from the UK: impact of penicillin-binding protein-3 inserts and CMY-42 beta-lactamase in Escherichia coli. Int J Antimicrob Agents. 2023:106776. https://doi.org/10.1016/j.ijantimicag.2023.106776.